Name: NATERA INC (NTRA) Stock
Brand: NATERA INC
Rating: 7 (3 reviews)

NTRA Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Chartmill

Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance

4 days ago - By: Benzinga - Mentions: STUB APP AMZN INSM ...

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves

7 days ago - By: Natera, Inc.

Natera Integrates with Flatiron Health’s OncoEMR® Platform

10 days ago - By: The Motley Fool

Natera (NTRA) Q3 2025 Earnings Call Transcript

12 days ago - By: Zacks Investment Research

Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings

12 days ago - By: Zacks Investment Research - Mentions: SGRY

Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates

12 days ago - By: Natera, Inc.

Natera Reports Third Quarter 2025 Financial Results

13 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

19 days ago - By: Natera, Inc.

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

20 days ago - By: Natera, Inc.

Natera to Report its Third Quarter Results on November 6, 2025

22 days ago - By: Natera, Inc.

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

23 days ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Natera, Inc.

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

a month ago - By: Natera, Inc.

Natera Named to Fast Company’s Next Big Things in Tech List

a month ago - By: Natera, Inc.

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

a month ago - By: Natera, Inc.

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

2 months ago - By: Natera, Inc.

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

2 months ago - By: Natera, Inc.

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

2 months ago - By: Natera, Inc.

NATERA INC (NTRA) Stock News

NTRA Latest News, Press Relases and Analysis

Natera Inc (NASDAQ:NTRA) Q3 2025 Earnings: Revenue Soars Past Estimates, Shares Climb on Raised Guidance

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves

Natera Integrates with Flatiron Health’s OncoEMR® Platform

Natera (NTRA) Q3 2025 Earnings Call Transcript

Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings

Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates

Natera Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 6, 2025

Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT

Natera to Report its Third Quarter Results on November 6, 2025

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights

Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients

Natera Named to Fast Company’s Next Big Things in Tech List

Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings

Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium

Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT

Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer

Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows